CTIC raised $55.8mn in 2/18 and now has a cash runway thru 2019 developing a compound for those ineligible for Ruxolitinib. CELG also has interest in the area, have recently acquired a similar compound FDA clinical hold has been lifted by moving forward with a lower dose. During the clinical hold, FDA allowed compassionate use of the compound In 3Q18, MAA will decide on marketing approval. 1Q19, MAA will read out Ph3.